AF-353 is a potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | AF-353 (Ro-4) is a potent, selective, and orally bioavailable antagonist of P2X3 and P2X2/3 receptors, with a pIC50 of 8.0 for both human and rat P2X3, and a pIC50 of 7.3 for human P2X2/3[1][2]. |
体内研究 | AF-353 (Ro-4) does not affect oxygen levels or cardiac function[2]. AF-353 (Ro-4), administered intravenously at doses of 10 mg/kg and 20 mg/kg for 4-6 hours, suppresses the purinergic response in both normal and spinal cord-injured (SCI) rats[2]. During the same treatment, AF-353 (Ro-4) reduces the inter-contractile interval in normal rats but not in SCI rats, while significantly lowering the frequency of non-voiding contractions in SCI rats[2]. |
体外研究 | AF-353 (Ro-4) strongly inhibits α,β-meATP-evoked intracellular calcium flux in cell lines expressing recombinant rat and human P2X3, as well as human P2X2/3 channels[1]. AF-353 (Ro-4) also inhibits human P2X2/3 channel function, though with slightly less potency, indicated by a p50 of 7.3[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.49mL 2.50mL 1.25mL |
24.99mL 5.00mL 2.50mL |
CAS号 | 865305-30-2 |
分子式 | C14H17IN4O2 |
分子量 | 400.215 |
别名 | Ro-4 |
运输 | 蓝冰 |
存储条件 |
粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 105 mg/mL(262.36 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |